Literature DB >> 21179530

Diagnosis and management of essential tremor and dystonic tremor.

Alexandre Gironell1, Jaime Kulisevsky.   

Abstract

Essential tremor (ET) is the most common adult movement disorder. Traditionally considered as a benign disease, it can cause an important physical and psychosocial disability. Drug treatment for ET remains poor and often unsatisfactory. Current therapeutic strategies for ET are reviewed according to the level of discomfort caused by tremor. For mild tremor, nonpharmacological strategies consist of alcohol and acute pharmacological therapy; for moderate tremor, pharmacological therapies (propranolol, gabapentin, primidone, topiramate, alprazolam and other drugs); and for severe tremor, the role of functional surgery is emphasised (thalamic deep brain stimulation, thalamotomy). The more specific treatment of head tremor with the use of botulinum toxin is also discussed. Several points are discussed to guide the immediate research into this disease in the near future. Dystonic tremor is a common symptom in dystonia. Diagnostic criteria for dystonic tremor and differential diagnosis with psychogenic tremor and ET are described. Treatment of dystonic tremor matches the treatment of dystonia. In cases of symptomatic dystonic tremor similar to ET, therapeutic strategies would be the same as for ET.

Entities:  

Keywords:  alprazolam; deep brain stimulation; essential tremor; gabapentin; primidone; propranolol; topiramate

Year:  2009        PMID: 21179530      PMCID: PMC3002636          DOI: 10.1177/1756285609104791

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  39 in total

Review 1.  Essential tremor.

Authors:  Elan D Louis
Journal:  Lancet Neurol       Date:  2005-02       Impact factor: 44.182

2.  Intrafamilial correlation in idiopathic torsion dystonia.

Authors:  N A Fletcher; A E Harding; C D Marsden
Journal:  Mov Disord       Date:  1991       Impact factor: 10.338

3.  beta-Adrenoreceptor antagonists in essential tremor.

Authors:  D Jefferson; P Jenner; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-10       Impact factor: 10.154

4.  Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial.

Authors:  W Ondo; C Hunter; K D Vuong; K Schwartz; J Jankovic
Journal:  Mov Disord       Date:  2000-07       Impact factor: 10.338

5.  The effect of nimodipine on essential tremor.

Authors:  N Biary; Y Bahou; M A Sofi; W Thomas; S M al Deeb
Journal:  Neurology       Date:  1995-08       Impact factor: 9.910

6.  Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials.

Authors:  Gregory S Connor; Keith Edwards; Daniel Tarsy
Journal:  Clin Neuropharmacol       Date:  2008 Mar-Apr       Impact factor: 1.592

7.  Tremor and idiopathic dystonia.

Authors:  C P Jedynak; A M Bonnet; Y Agid
Journal:  Mov Disord       Date:  1991       Impact factor: 10.338

8.  Effect of alcohol on tremors: comparison with propranolol.

Authors:  W C Koller; N Biary
Journal:  Neurology       Date:  1984-02       Impact factor: 9.910

9.  Levetiracetam is not effective for essential tremor.

Authors:  Rodger J Elble; Kelly E Lyons; Rajesh Pahwa
Journal:  Clin Neuropharmacol       Date:  2007 Nov-Dec       Impact factor: 1.592

10.  A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor.

Authors:  Theresa A Zesiewicz; Christopher L Ward; Robert A Hauser; Jason L Salemi; Shaila Siraj; Maria-Carmen Wilson; Kelly L Sullivan
Journal:  Mov Disord       Date:  2007-08-15       Impact factor: 10.338

View more
  16 in total

Review 1.  Rest tremor in dystonia: epidemiology, differential diagnosis, and pathophysiology.

Authors:  Navnika Gupta; Sanjay Pandey
Journal:  Neurol Sci       Date:  2020-04-23       Impact factor: 3.307

2.  The spiral axis as a clinical tool to distinguish essential tremor from dystonia cases.

Authors:  Monika Michalec; Nora Hernandez; Lorraine N Clark; Elan D Louis
Journal:  Parkinsonism Relat Disord       Date:  2014-02-07       Impact factor: 4.891

3.  Defining differences in patient characteristics between spasmodic dysphonia and laryngeal tremor.

Authors:  Priyesh N Patel; Edmond K Kabagambe; Jennifer C Starkweather; Matthew Keller; Zaki A Ahmed; Simone C Gruber; Jordan S Akins; C Gaelyn Garrett; David O Francis
Journal:  Laryngoscope       Date:  2018-11-13       Impact factor: 3.325

4.  Sensory trick with metoclopramide-associated tardive tremor.

Authors:  David Shprecher
Journal:  BMJ Case Rep       Date:  2012-09-07

5.  Electrophysiological characteristics of task-specific tremor in 22 instrumentalists.

Authors:  André Lee; Kenta Tominaga; Shinichi Furuya; Fumio Miyazaki; Eckart Altenmüller
Journal:  J Neural Transm (Vienna)       Date:  2014-07-25       Impact factor: 3.575

Review 6.  Magnetic Resonance-Guided Focused Ultrasound Neurosurgery for Essential Tremor: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2018-05-03

7.  Tremor: clinical phenomenology and assessment techniques.

Authors:  Christopher W Hess; Seth L Pullman
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-06-28

8.  Postural hand tremor and incident hypertension in young to middle-aged adults: the Bogalusa heart study.

Authors:  Tian Hu; Jack M Guralnik; Lu Yao; Jeanette Gustat; Emily W Harville; Larry S Webber; Wei Chen; Jiang He; Paul K Whelton; Lydia A Bazzano
Journal:  J Hypertens       Date:  2016-07       Impact factor: 4.844

9.  Sustained Medication Reduction Following Unilateral VIM Thalamic Stimulation for Essential Tremor.

Authors:  Andrew S Resnick; Michael S Okun; Teresita Malapira; Donald Smith; Fernando L Vale; Kelly Sullivan; Amber Miller; Israt Jahan; Theresa Zesiewicz
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-04-06

10.  Cognitive subtypes in individuals with essential tremor seeking deep brain stimulation.

Authors:  Adrianna M Ratajska; Francesca V Lopez; Lauren Kenney; Charles Jacobson; Kelly D Foote; Michael S Okun; Dawn Bowers
Journal:  Clin Neuropsychol       Date:  2021-02-10       Impact factor: 4.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.